PE20030800A1 - Forma de dosificacion oral de liberacion controlada - Google Patents
Forma de dosificacion oral de liberacion controladaInfo
- Publication number
- PE20030800A1 PE20030800A1 PE2003000145A PE2003000145A PE20030800A1 PE 20030800 A1 PE20030800 A1 PE 20030800A1 PE 2003000145 A PE2003000145 A PE 2003000145A PE 2003000145 A PE2003000145 A PE 2003000145A PE 20030800 A1 PE20030800 A1 PE 20030800A1
- Authority
- PE
- Peru
- Prior art keywords
- openings
- dosage form
- erosionable
- solvate
- erosion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
QUE COMPRENDE: a)UN NUCLEO EROSIONABLE, QUE ESTA COMPUESTO POR: i)UNA BASE DEBIL FARMACEUTICAMENTE ACTIVA O UNA SAL O SOLVATO DE LA MISMA: b)UN RECUBRIMIENTO EROSIONABLE EN TORNO A DICHO NUCLEO, CUYO ESPESOR ES DE 0,05 mm A 0,5 mm, QUE COMPRENDE UNA O MAS ABERTURAS QUE SE EXTIENDEN COMPLETAMENTE A TRAVES DE DICHO RECUBRIMIENTO, PERO QUE NO PENETRAN EN (a) Y QUE COMUNICAN EL MEDIO DE USO CON (a); DONDE, LA LIBERACION DE (i) A PARTIR DE LA FORMA DE DOSIFICACION OCURRE A TRAVES DE LAS ABERTURAS POR EROSION DE (a) Y A TRAVES DE LA EROSION DE (b) EN CONDICIONES DE pH MAYOR A 4,5. ASIMISMO, EL MATERIAL DE (b) ES SELECCIONADO DE: POLIMEROS DE POLIMETACRILATO, POLI(ACETATO-FTALATO DE VINILO) COPROCESADO, ACETATO-TRIMELITATO DE CELULOSA, ACETATO-FTALLATO DE CELULOSA, LACA, POLIMEROS DE FTALATO DE HIDROXIPROPILMETILCELULOSA Y SUS COPOLIMEROS, Y MEZCLAS DE ELLOS; EL NUCLEO ES PREDOMINANTEMENTE HIDROXIPROPILMETILCELULOSA Y LACTOSA; LA BASE DEBIL ES 5-[4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]BENCIL]TIAZOLIDIN-2,4-DIONA O UNA SAL O SOLVATO FARMACEUTICAMENTE ACEPTABLE DE LA MISMA; Y, EL TAMANO DE LAS ABERTURAS ESTAN EN EL INTERVALO DE 5 mm A 8 mm. SE REFIERE TAMBIEN AL PROCEDIMIENTO PARA PREPARAR DICHA FORMA DE DOSIFICACION
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0203297A GB0203297D0 (en) | 2002-02-12 | 2002-02-12 | Novel composition |
GBGB0203296.9A GB0203296D0 (en) | 2002-02-12 | 2002-02-12 | Novel composition |
GB0203298A GB0203298D0 (en) | 2002-02-12 | 2002-02-12 | Novel composition |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030800A1 true PE20030800A1 (es) | 2003-10-31 |
Family
ID=27738830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000145A PE20030800A1 (es) | 2002-02-12 | 2003-02-10 | Forma de dosificacion oral de liberacion controlada |
Country Status (34)
Country | Link |
---|---|
EP (1) | EP1474114B1 (es) |
JP (2) | JP2005526031A (es) |
KR (2) | KR101048925B1 (es) |
CN (1) | CN100444833C (es) |
AP (1) | AP1736A (es) |
AR (1) | AR038417A1 (es) |
AT (1) | ATE455540T1 (es) |
AU (1) | AU2003245763B2 (es) |
BR (1) | BRPI0307319B8 (es) |
CA (1) | CA2475544A1 (es) |
CL (1) | CL2007003010A1 (es) |
CO (1) | CO5601025A2 (es) |
CY (1) | CY1109939T1 (es) |
DE (1) | DE60331041D1 (es) |
DK (1) | DK1474114T3 (es) |
EA (1) | EA008286B1 (es) |
EC (1) | ECSP045232A (es) |
ES (1) | ES2336319T3 (es) |
HK (1) | HK1072194A1 (es) |
IL (1) | IL163098A (es) |
IS (1) | IS2747B (es) |
MA (1) | MA27689A1 (es) |
MX (1) | MXPA04007794A (es) |
MY (1) | MY139719A (es) |
NO (1) | NO334453B1 (es) |
NZ (1) | NZ534152A (es) |
OA (1) | OA12770A (es) |
PE (1) | PE20030800A1 (es) |
PL (1) | PL206596B1 (es) |
PT (1) | PT1474114E (es) |
SI (1) | SI1474114T1 (es) |
TW (1) | TWI286079B (es) |
UY (1) | UY27660A1 (es) |
WO (1) | WO2003068195A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0120835D0 (en) | 2001-08-28 | 2001-10-17 | Smithkline Beecham Plc | Process |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
AR045330A1 (es) * | 2003-08-07 | 2005-10-26 | Sb Pharmco Inc | Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla |
GB0318824D0 (en) * | 2003-08-11 | 2003-09-10 | Glaxo Group Ltd | Novel composition |
US7879354B2 (en) | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
EP2363117B1 (en) * | 2006-01-27 | 2015-08-19 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids |
RU2428176C2 (ru) * | 2006-01-27 | 2011-09-10 | Юранд, Инк. | Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2150830B (en) * | 1983-12-05 | 1987-08-19 | Alza Corp | Drug dispenser |
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
SI1131070T1 (sl) * | 1998-11-12 | 2008-12-31 | Smithkline Beecham Plc | Farmacevtski sestavek za modificirano sproĺ äśanje senzibilizatorja za inzulin in metformina |
AR023699A1 (es) * | 1998-11-12 | 2002-09-04 | Smithkline Beecham Corp | Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica |
GB0027471D0 (en) * | 2000-11-08 | 2000-12-27 | Smithkline Beecham Plc | Processes |
-
2003
- 2003-02-10 MY MYPI20030447A patent/MY139719A/en unknown
- 2003-02-10 PE PE2003000145A patent/PE20030800A1/es active IP Right Grant
- 2003-02-11 TW TW092102772A patent/TWI286079B/zh not_active IP Right Cessation
- 2003-02-11 UY UY27660A patent/UY27660A1/es not_active IP Right Cessation
- 2003-02-11 AR ARP030100422A patent/AR038417A1/es not_active Application Discontinuation
- 2003-02-12 CA CA002475544A patent/CA2475544A1/en not_active Abandoned
- 2003-02-12 EP EP03739557A patent/EP1474114B1/en not_active Expired - Lifetime
- 2003-02-12 DK DK03739557.1T patent/DK1474114T3/da active
- 2003-02-12 EA EA200401071A patent/EA008286B1/ru not_active IP Right Cessation
- 2003-02-12 OA OA1200400209A patent/OA12770A/en unknown
- 2003-02-12 ES ES03739557T patent/ES2336319T3/es not_active Expired - Lifetime
- 2003-02-12 BR BRPI0307319A patent/BRPI0307319B8/pt not_active IP Right Cessation
- 2003-02-12 AT AT03739557T patent/ATE455540T1/de active
- 2003-02-12 KR KR1020047012361A patent/KR101048925B1/ko active IP Right Grant
- 2003-02-12 CN CNB038037378A patent/CN100444833C/zh not_active Expired - Lifetime
- 2003-02-12 AP APAP/P/2004/003087A patent/AP1736A/en active
- 2003-02-12 MX MXPA04007794A patent/MXPA04007794A/es active IP Right Grant
- 2003-02-12 PT PT03739557T patent/PT1474114E/pt unknown
- 2003-02-12 WO PCT/GB2003/000594 patent/WO2003068195A1/en active Application Filing
- 2003-02-12 SI SI200331764T patent/SI1474114T1/sl unknown
- 2003-02-12 DE DE60331041T patent/DE60331041D1/de not_active Expired - Lifetime
- 2003-02-12 NZ NZ534152A patent/NZ534152A/en not_active IP Right Cessation
- 2003-02-12 AU AU2003245763A patent/AU2003245763B2/en not_active Expired
- 2003-02-12 JP JP2003567378A patent/JP2005526031A/ja not_active Withdrawn
- 2003-02-12 PL PL371368A patent/PL206596B1/pl unknown
- 2003-02-12 KR KR1020107015064A patent/KR20100086084A/ko not_active Application Discontinuation
-
2004
- 2004-07-19 IL IL163098A patent/IL163098A/en active IP Right Grant
- 2004-08-05 IS IS7383A patent/IS2747B/is unknown
- 2004-08-09 CO CO04077244A patent/CO5601025A2/es not_active Application Discontinuation
- 2004-08-12 EC EC2004005232A patent/ECSP045232A/es unknown
- 2004-08-12 MA MA27822A patent/MA27689A1/fr unknown
- 2004-08-31 NO NO20043633A patent/NO334453B1/no not_active IP Right Cessation
-
2005
- 2005-04-25 HK HK05103523.5A patent/HK1072194A1/xx not_active IP Right Cessation
-
2007
- 2007-10-19 CL CL2007003010A patent/CL2007003010A1/es unknown
-
2010
- 2010-03-31 CY CY20101100304T patent/CY1109939T1/el unknown
- 2010-04-22 JP JP2010098906A patent/JP5279757B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030800A1 (es) | Forma de dosificacion oral de liberacion controlada | |
ATE512659T1 (de) | Tablette mit verzögerter wirkstofffreigabe und bestimmter formgeometrie | |
NO992097L (no) | Polymerholdig preparat med kontrollert avgivelse av aktiv forbindelse | |
PT1385489E (pt) | Granulados revestidos tendo por base inibidores da enzima de conversao de angiotensina | |
ES2548878T3 (es) | Métodos de tratamiento de úlceras de la piel | |
ID29125A (id) | Mekanisme penopang bonggol dan aktuator piesoelektrik film tipis | |
BR9905923A (pt) | Agente de liberação de elemento de transferência/transfusão e métodos do mesmo | |
SG130190A1 (en) | Method and device for enhancing transdermal agent flux | |
DK1727551T3 (da) | Farmaceutisk sammensætning omfattende et benzodiazepinderivat og en inhibitor af RSV-fusionsproteinet | |
DK2258346T3 (da) | Fast farmaceutisk doseringsform omfattende en fast dispersion af en hiv-proteaseinhibitor | |
WO2002090245A3 (en) | Methods of forming microstructure devices | |
BRPI0515776A (pt) | auxiliares de retenção e drenagem | |
HRP20050557A2 (en) | Method for improving the pharmacokinetics of a nnrti | |
EP2072043A3 (en) | Mesalazine tablet | |
ITMI20021928A1 (it) | Apparecchiatura per la finitura di una superficie ottica di | |
PT1355635E (pt) | Novo revestimento de pelicula | |
ITTO991137A0 (it) | Monomeri di reticolazione per fotoresist e procedimento per la prepara zione di polimeri fotoresist utilizzanti tali monomeri. | |
ITRM20020529A1 (it) | Polimeri sterilizzanti, processo di loro preparazione ed uso. | |
CY1106226T1 (el) | Μεσυλικο αλας 5-[4-[2-(ν-μεθυλ-ν-(2-πυριδυλ)αμινο)αιθοξυ]βενζυλ]θειαζολιδινο-2,4-διονης | |
AU2003272770A1 (en) | Method and aparatus for dry releasing lenses from an anterior mold half | |
TW200717515A (en) | Method of manufacturing a stamper for replicating a high density relief structure | |
CY1105354T1 (el) | Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο | |
ATE304736T1 (de) | Mikro-elektromechanisches system und verfahren zu dessen herstellung | |
EA200300345A1 (ru) | Гидрохлоридная соль 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона | |
DK1446404T3 (da) | Rosiglitazonedisylater og deres anvendelse som antidiabetika |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |